203 related articles for article (PubMed ID: 8289483)
1. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines.
Cullis JO; Barrett AJ; Goldman JM; Lechler RI
Leukemia; 1994 Jan; 8(1):165-70. PubMed ID: 8289483
[TBL] [Abstract][Full Text] [Related]
2. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
3. Intracellular transport of class I MHC molecules in antigen processing mutant cell lines.
Anderson KS; Alexander J; Wei M; Cresswell P
J Immunol; 1993 Oct; 151(7):3407-19. PubMed ID: 8376783
[TBL] [Abstract][Full Text] [Related]
4. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.
Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Roberts W; Scheinberg DA
Haematologica; 2005 Oct; 90(10):1324-32. PubMed ID: 16219568
[TBL] [Abstract][Full Text] [Related]
5. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia.
Barrett J; Guimaraes A; Cullis J; Goldman JM
Stem Cells; 1993 Oct; 11 Suppl 3():104-8. PubMed ID: 8298471
[TBL] [Abstract][Full Text] [Related]
6. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I-B35 molecules: relationship between antigen defective cell lines and HLA frequencies in CML patients.
Martinelli G; Zaccaria A; Saglio G; Zuffa E; Farabegoli P; Testoni N; Conte R; Tura S
Leukemia; 1995 Oct; 9(10):1795-6. PubMed ID: 7564530
[No Abstract] [Full Text] [Related]
7. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
[TBL] [Abstract][Full Text] [Related]
8. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes.
Greco G; Fruci D; Accapezzato D; Barnaba V; Nisini R; Alimena G; Montefusco E; Vigneti E; Butler R; Tanigaki N; Tosi R
Leukemia; 1996 Apr; 10(4):693-9. PubMed ID: 8618449
[TBL] [Abstract][Full Text] [Related]
9. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.
Bocchia M; Wentworth PA; Southwood S; Sidney J; McGraw K; Scheinberg DA; Sette A
Blood; 1995 May; 85(10):2680-4. PubMed ID: 7742526
[TBL] [Abstract][Full Text] [Related]
10. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS
Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136
[TBL] [Abstract][Full Text] [Related]
11. Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).
Mundhada S; Luthra R; Cano P
BMC Cancer; 2004 Jun; 4():25. PubMed ID: 15202948
[TBL] [Abstract][Full Text] [Related]
12. Assessment of major histocompatibility complex class I interaction with Epstein-Barr virus and human immunodeficiency virus peptides by elevation of membrane H-2 and HLA in peptide loading-deficient cells.
Stuber G; Modrow S; Höglund P; Franksson L; Elvin J; Wolf H; Kärre K; Klein G
Eur J Immunol; 1992 Oct; 22(10):2697-703. PubMed ID: 1327802
[TBL] [Abstract][Full Text] [Related]
13. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.
De Bruijn ML; Schumacher TN; Nieland JD; Ploegh HL; Kast WM; Melief CJ
Eur J Immunol; 1991 Dec; 21(12):2963-70. PubMed ID: 1660811
[TBL] [Abstract][Full Text] [Related]
14. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides.
Wei ML; Cresswell P
Nature; 1992 Apr; 356(6368):443-6. PubMed ID: 1557127
[TBL] [Abstract][Full Text] [Related]
15. Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition.
Sheil JM; Schell TD; Shepherd SE; Klimo GF; Kioschos JM; Paterson Y
Eur J Immunol; 1994 Sep; 24(9):2141-9. PubMed ID: 7522163
[TBL] [Abstract][Full Text] [Related]
16. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
17. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay.
Stuber G; Leder GH; Storkus WT; Lotze MT; Modrow S; Székely L; Wolf H; Klein E; Kärre K; Klein G
Eur J Immunol; 1994 Mar; 24(3):765-8. PubMed ID: 8125143
[TBL] [Abstract][Full Text] [Related]
18. Presentation of viral antigens restricted by H-2Kb, Db or Kd in proteasome subunit LMP2- and LMP7-deficient cells.
Zhou X; Momburg F; Liu T; Abdel Motal UM; Jondal M; Hämmerling GJ; Ljunggren HG
Eur J Immunol; 1994 Aug; 24(8):1863-8. PubMed ID: 8056044
[TBL] [Abstract][Full Text] [Related]
19. A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class I product.
Guimezanes A; Schumacher TN; Ploegh HL; Schmitt-Verhulst AM
Eur J Immunol; 1992 Jun; 22(6):1651-4. PubMed ID: 1318201
[TBL] [Abstract][Full Text] [Related]
20. The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.
MacIntyre AR; Christmas SE; Clark RE
Exp Hematol; 1996 Sep; 24(11):1307-11. PubMed ID: 8862441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
